Skip to main content

Table 3 Adverse events (AEs) occurring in more than 10% of either treatment group

From: Customized chemotherapy based on epidermal growth factor receptormutation status for elderly patients with advanced non-small-cell lung cancer: a phase II trial

Gefitinib (N = 22) All Grades CTC Grade 3 or 4
Skin-related AEs 14 (63.6%) 1 (4.5%)
ALT 14 (63.6%) 5 (22.7%)
AST 12 (54.5%) 3 (13.6%)
Anemia 11 (50.0%) 0
Hypoalbminemia 9 (40.9%) 0
Anorexia 6 (27.3%) 0
Fatigue 6 (27.3%) 0
Diarrhea 6 (27.3%) 0
ALP 6 (27.3%) 0
VNR or GEM (N = 32) All Grades CTC Grade 3 or 4
Anemia 23 (71.9%) 4 (12.5%)
Leukocytopenia 21 (65.6%) 15 (46.9%)
Neutropenia 20 (62.5%) 15 (46.9%)
Fatigue 18 (56.3%) 2 (6.3%)
Anorexia 12 (37.5%) 3 (9.4%)
Thrombocytopenia 12 (37.5%) 1 (3.1%)
ALT 12 (37.5%) 0
Nausea 11 (34.4%) 2 (6.3%)
Constipation 9 (28.1%) 1 (3.1%)
AST 9 (28.1%) 0
Hyponatremia 5 (15.6%) 2 (6.3%)
Hyperkalemia 5 (15.6%) 0
Hypocalcemia 5 (15.6%) 0
Febrile neutropenia 4 (12.5%) 4 (12.5%)
  1. AE: adverse event; ALT: alanine aminotransferase; ALP: alkaline phosphatase; AST: aspartate aminotransferase; CTC: common toxicity criteria; GEM: gemcitabine; VNR: vinorelbine.